Furthermore, the FDA has approved HE4 and CA-125 as biomarkers to determine the risk of ovarian cancer in women with undiagnosed pelvic mass (Yoshida et al., 2016); however, measuring these biomarkers is not currently fully recommended by the NCCN and is regarded as optional by other professional organizations such as the Society of Gynecologic Oncologists (SGO) (Salani et al., 2011). The gene discussed is MUC16; the disease is ovarian cancer.